Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
Sthanu Subramanian, Pediatrician, shared a post on X about a recent article by Noel C. Chan et al. published in Arteriosclerosis, Thrombosis, and Vascular Biology, adding:
“Dabigatran and Mechanical heart valves.
Dabigatran (Pradaxa) is contraindicated for mechanical heart valves because it is significantly less effective at preventing blood clots on artificial valves and carries a higher risk of major bleeding compared to traditional treatments like Warfarin.
The danger of using dabigatran in these patients was proven by the RE-ALIGN Trial, which was stopped early due to severe safety risks.
The specific reasons for this include:
1. Higher Rates of Valve Thrombosis:
Dabigatran only targets one specific clotting factor (thrombin).
Mechanical valves are highly prone to clot formation, and warfarin’s broader mechanism of action is much more effective at preventing clots from building up on the artificial material.
2. Increased Risk of Strokes:
Because dabigatran fails to adequately prevent clots from forming on the valves, users experienced more strokes and systemic embolisms.
3. Excessive Bleeding:
The drug also led to a significantly higher rate of major bleeding events, including dangerous bleeding in the pericardial space surrounding the heart.
4. Absorption Issues:
Dabigatran has very low oral bioavailability and can cause topical anticoagulant effects in the gastrointestinal tract, contributing to higher bleeding risks.
Mechanisms of mechanical heart valve thrombosis and the differential effects of anticoagulants on thrombin generation.”
Title: Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective?
Authors: Noel C. Chan, Jeffrey I. Weitz, John W. Eikelboom

Other posts featuring Sthanu Subramanian on Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week